Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data

A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sjögren’s, showing potential utility across multiple autoimmune indications.